RecruitingNCT05406232
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Quantifying Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Sponsor
M.D. Anderson Cancer Center
Enrollment
12 participants
Start Date
Sep 15, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patients \>= 18 years of age with biopsy proven invasive breast cancer
- Breast cancer that appears to be superficially accessible to a tumor punch biopsy
- Patients thought to derive clinical benefit from palliative RT to the breast/chestwall
- In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT
Exclusion Criteria4
- A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered
- Pregnancy
- Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies
- Receipt of immunotherapy or chemotherapy 7 days prior to start of RT
Interventions
PROCEDUREBiopsy
Undergo tumor punch biopsy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
RADIATIONRadiation Therapy
Undergo RT
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05406232
Related Trials
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
NCT071374161 location
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT0360696730 locations
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT059415204 locations
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT0618475011 locations